Rimonabant, a selective CB1 antagonist, was developed for the treatment of obesity and metabolic syndrome due to its effects on weight loss, appetite suppression, and loss of visceral fat but was removed from the market due to serious side effects (depression, anxiety, and suicidality) in patients with a history of depressive symptoms [70,71]. This evidence concerns the gene CNR1 and depressive symptom measurement.